YMAB 4-DAY DEADLINE ALERT: Hagens Berman Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys Before Mar. 20th Deadline in Securities Fraud Class Action
March 16, 2023 12:17 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now. Class Period:...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys Before Mar. 20th Deadline in Securities Fraud Class Action
March 11, 2023 15:49 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now. Class Period:...
YMAB 2-WEEK DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending
March 06, 2023 16:01 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now. Class Period:...
YMAB SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed
February 27, 2023 17:07 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now. Class Period: Oct....
YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Filed
February 20, 2023 10:05 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now. Class Period:...
YMAB LAWSUIT ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending
February 13, 2023 11:30 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now. Class Period: Oct....
YMAB FRAUD ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Filed
February 06, 2023 15:56 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now. Class Period: Oct....
YMAB ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Fraud Class Action Filed
January 30, 2023 15:28 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now. Class...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Fraud Class Action Filed
January 19, 2023 18:09 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now. Class Period:...
YMAB INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations
November 17, 2022 13:03 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now. Visit:...